Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Cinisello Balsamo – page 100

2 955 clinical trials in Cinisello Balsamo, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Cinisello Balsamo at a glance
2 955
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 955 trials in Cinisello Balsamo

Open in trial search

Osimertinib and drug combination in metastatic non‑small cell lung cancer with targetable genomic driver alterations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Universita' Degli Studi Di Torino

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer

Not yet recruiting

Ivonescimab with drug combination in patients with asymptomatic brain metastases from non‑small cell lung cancer – randomized phase II trial

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Abemaciclib plus drug combination in women with early-stage hormone‑positive HER2‑negative breast cancer: phase II study to reduce chemotherapy and surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Sjogren's syndrome

Not yet recruiting

A Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Graves' disease

Not yet recruiting

A Randomized Study of Felzartamab versus Placebo to Assess Efficacy and Safety in Adults with Graves’ Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Felzartamab
  • Sponsor:Biogen Idec Research Limited

Study of VSA012 Sodium in Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Complement Inhibitor‑Naïve or Have Persistent Anemia on C5 Inhibitor Therapy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Bisirna Therapeutics Pte. Ltd.

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Type 2 diabetes mellitus

Not yet recruiting

Evaluation of Long-Term Efficacy and Safety of Tirzepatide Versus Intensified Conventional Care in Early Treatment of Type 2 Diabetes in Adults

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Albiglutide
  • Sponsor:Eli Lilly & Co.

Alcoholic liver disease

Not yet recruiting

Safety and Efficacy of Efimosfermin Alfa vs Placebo in Adults with Alcohol-Related Liver Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Breast cancer+1

Not yet recruiting

Long‑term safety study of alpelisib alone or with fulvestrant in adults with breast cancer who benefited from previous alpelisib treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Cinisello Balsamo

What the registry says about research in the country

01 Mental Health Research

Innovative research focusing on Major Depressive Disorder with concurrent insomnia symptoms, evaluating new combination therapies alongside existing antidepressant treatments. Studies examine the effectiveness of adjunctive medications in improving depressive symptoms and sleep patterns.

  • Depression with Insomnia
  • Antidepressant Augmentation
  • Long-term Treatment Efficacy

Research aims to enhance treatment outcomes for patients who haven't responded adequately to conventional therapies.

02 Cardiovascular Studies

Advanced clinical research examining atherosclerotic cardiovascular disease prevention and treatment. Studies include innovative approaches to blood clot prevention in patients with irregular heartbeat who have undergone stent procedures.

  • Primary ASCVD Prevention
  • Anticoagulation Therapy
  • Post-PCI Treatment

Investigations focus on reducing major adverse cardiac events and improving patient outcomes.

03 Metabolic Disorders

Comprehensive studies targeting severe hypertriglyceridemia and related metabolic conditions. Multiple trials are evaluating new therapeutic approaches for managing elevated triglyceride levels and associated cardiovascular risks.

  • Triglyceride Management
  • Metabolic Disease Treatment
  • Cardiovascular Risk Reduction

Research focuses on developing effective treatments for patients with severe lipid disorders.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.